Sangamo team rushes to defend first human gene editing data as MPS II therapy offers a hit — and a miss
Sangamo $SGMO rolled out its first glimpse at the clinical efficacy of their gene editing therapy for Hunter syndrome (MPS II). And while researchers were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
